{
    "clinical_study": {
        "@rank": "168002", 
        "arm_group": [
            {
                "arm_group_label": "Immunosuppressed ICU Patients with lung infiltrates", 
                "description": "Immunosuppressed ICU Patients with lung infiltrates"
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population."
            }
        ], 
        "biospec_descr": {
            "textblock": "Only fungal DNA investigated"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The aim of this project is therefore to explore on the clinical significance of analyzing\n      surrogate markers combined with conventional diagnostics in the ICU setting. BAL, blood and\n      biopsy samples will be subjected to a combined analysis of GM, BDG, Aspergillus specific PCR\n      assays in addition to conventional diagnostics (Microscopy, Culture,Histology) for ICU pts\n      with pulmonary infiltrates.\n\n      As GM and BDG are not species-specific, three established and repeatedly published species\n      specific PCR-based assays (nested PCR, real time PCR assay, multifungal DNA Array)developed\n      by our group will be investigated in combination with the serological tests in a multicenter\n      prospective clinical diagnostic trial."
        }, 
        "brief_title": "Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "INvasive Aspergillosis", 
            "Mechanical Ventilation", 
            "Lung Infiltrates", 
            "Diagnostics", 
            "Biomarker"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aspergillosis", 
                "Lung Diseases, Interstitial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  underlying conditions (see above)\n\n          -  being on mechanical ventilation\n\n          -  lung infiltrates\n\n        Exclusion Criteria:\n\n          -  immunocompetent patients (not fulfilling the criteria above)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Immunocompromised patients on the intensive care  unit with lun infiltrates and one of the\n        following underlying conditions:\n\n          -  Underlying malignancy\n\n          -  Antineoplastic chemotherapy\n\n          -  Neutropenia\n\n          -  Allogeneic hematopoietic stem cell transplantation\n\n          -  Solid organ transplantation\n\n          -  Retransplantation\n\n          -  Acute or chronic immunological rejection or graft-versus-host-disease\n\n          -  Treatment with immunosuppressive agents (calcineurin inhibitors, OKT3, etc)\n\n          -  Profound systemic corticosteroid therapy prior to ICU admission\n\n          -  COPD Gold III/IV\n\n          -  Advanced liver cirrhosis and ICU treatment for more than 7 days\n\n          -  Hemodialysis, renal failure\n\n          -  CMV infection\n\n          -  HIV infection; CD4 cellcount\n\n          -  Post splenectomy\n\n          -  Post cardiac surgery\n\n          -  Diabetes mellitus\n\n          -  mechanical ventilation for more than 21 days\n\n          -  ICU-based steroid therapy and corticosteroid treatment for more than 7 days\n\n          -  Malnutrition\n\n          -  Severe burn wounds"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695499", 
            "org_study_id": "BAL-Biomarker-ICU Study", 
            "secondary_id": "Grant Pfizer ASPIRE Award"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "dieter.buchheidt@umm.de", 
                "last_name": "Dieter Buchheidt, MD", 
                "phone": "+49.621.383.4115"
            }, 
            "contact_backup": {
                "email": "mark.reinwald@umm.de", 
                "last_name": "Mark Reinwald, MD", 
                "phone": "+49.621.383.4115"
            }, 
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany", 
                    "zip": "68167"
                }, 
                "name": "Mannheim University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Dieter Buchheidt, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mark Reinwald, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, Beta D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Real-time qPCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL)and Blood Samples of Intensive Care Unit Patients With Pulmonary Infiltrates", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: University of Heidelberg", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of diagnostic accuracy of the combined biomarker approach", 
            "measure": "Diagnostic accuracy of combined biomarker testing in BAL fluid in relation to diagnostic certainty", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "reference": [
            {
                "PMID": "22740590", 
                "citation": "Reinwald M, Hummel M, Kovalevskaya E, Spiess B, Heinz WJ, Vehreschild JJ, Schultheis B, Krause SW, Claus B, Suedhoff T, Schwerdtfeger R, Reuter S, Kiehl MG, Hofmann WK, Buchheidt D. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother. 2012 Sep;67(9):2260-7. doi: 10.1093/jac/dks208. Epub 2012 Jun 27."
            }, 
            {
                "PMID": "22650156", 
                "citation": "Reinwald M, Spiess B, Heinz WJ, Vehreschild JJ, Lass-Fl\u00f6rl C, Kiehl M, Schultheis B, Krause SW, Wolf HH, Bertz H, Maschmeyer G, Hofmann WK, Buchheidt D. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012 Aug;89(2):120-7. doi: 10.1111/j.1600-0609.2012.01806.x. Epub 2012 Jun 22. PubMed PMID: 22650156."
            }, 
            {
                "PMID": "22526309", 
                "citation": "Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, Hofmann WK, Buchheidt D. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother. 2012 Jul;56(7):3905-10. doi: 10.1128/AAC.05902-11. Epub 2012 Apr 23."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695499"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Heidelberg", 
            "investigator_full_name": "Dieter Buchheidt", 
            "investigator_title": "Professor Dr. Dieter Buchheidt", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Heidelberg University", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Heidelberg University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}